Medigen Biotechnology Corp. announced The Ministry of Health and Welfare has approved the collaborative autologous Gamma-Delta T cell therapy project by the company and Chi Mei Hospital, Liouying. Cause of occurrence: Medigen, in collaboration with Chi Mei Medical Foundation, Liouying Chi Mei Hospital (referred to as Chi Mei Hospital, Liouying), has applied for the Autologous Gamma-Delta T Cell (Magicell-GDT) cell therapy project.

On March 28, 2024, Medigen received the approval letter from the competent authority, the Ministry of Health and Welfare, confirming that Medigen's Cell Processing Unit is compliant with Good Tissue Practice (GTP). In accordance with the regulations of the Regulations Governing the Application of Specific Medical Examination Technique and Medical Device, the Magicell-GDT cells produced at Medigen?s Cell Processing Unit can be used for treating stage IV solid tumors at Chi Mei Hospital, Liouying. Details on the approved items in the Chi Mei Hospital, Liouying cell therapy project: A. Type of cell therapy: Autologous Gamma-Delta T cell (Magicell-GDT); B. Indication: Stage IV solid tumor; Lung cancer, breast cancer, kidney cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric cancer, liver cancer, endometrial cancer, colorectal cancer; C. Cell processing unit: Medigen?s cell processing unit; D. Approval period: From March 27, 2024 to February 2, 2026.